Dycholium

Quick links to important sections

Dycholium

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dycholium

Quick Facts

Property Description
Active Ingredient Dehydrocholic acid (DHA)
Pharmacological Class Cholagogue / Choleretic
Typical Form Tablet
Origin Semi-synthetic bile acid
Former Manufacturer Novartis Consumer Health Canada Inc.

1. What is Dycholium, and what is its main purpose?

Dycholium is a medicine containing the active ingredient dehydrocholic acid (DHA), which belongs to the therapeutic sub-class of Cholagogues and Choleretics. This pharmacological class is clinically recognized for its ability to modulate bile flow and production in the liver.

Its primary purpose is to offer supportive treatment for the biliary system and overall hepatic function. By stimulating bile flow, Dycholium aids in the body's natural digestive processes and the efficient clearance of substances from the liver. This mechanism increases bile secretion volume.

2. What distinguishes Dycholium and its composition?

The key differentiating feature of Dycholium is its composition: it is a semi-synthetic bile acid derived from the chemical modification of natural cholic acid. This manufacturing process, previously associated with companies like Novartis Consumer Health Canada Inc., ensures a potent and standardized product, distinguishing it from crude plant-based remedies.

The medication is formulated for oral administration and the structure of dehydrocholic acid makes it an effective tool for supporting biliary motility, earning it the label of a hydrocholeretic—an agent that specifically increases the volume of watery bile secreted by the liver.

Regulatory References

  1. Cholagogues and Choleretics (MeSH)

What side effects are possible with Dycholium?

Possible side effects and safety information

Adverse Reaction Scope

Adverse reactions associated with dehydrocholic acid (Dycholium) are documented by health authorities and primarily categorized based on System-Organ Classes (SOCs), reflecting the compound's effect on bile flow. Specific frequency classifications (e.g., 'common,' 'rare') are not uniformly established in current official regulatory labeling for the oral formulation, meaning incidence is generally considered not known.

Category Official Safety Description
System-Organ Classes Primarily Gastrointestinal disorders (e.g., diarrhea, abdominal discomfort, nausea, vomiting), but also includes Nervous System disorders (e.g., headache) and Skin and Subcutaneous Tissue disorders (e.g., rash, itching).
Serious Adverse Reactions Regulatory documents note the possibility of severe hypersensitivity reactions (acute allergic responses) as a clinically significant risk.
Time-Related Patterns Prolonged or excessive use may be associated with systemic effects, including the potential for electrolyte imbalances and impaired absorption of fat-soluble vitamins (A, D, E, K).

Safety-Related Restrictions

Regulatory agencies define specific, critical safety limitations for the use of this compound. Dycholium is contraindicated and should not be used in individuals diagnosed with a complete obstruction of the bile ducts or in cases of severe hepatitis or severe liver dysfunction.


Safety Profile Summary

This medicine's official safety profile is primarily structured around the expected physiological effects, with common reactions affecting the digestive system. The most crucial safety factor is the strict contraindication in patients with obstructed bile flow, which is a mandatory regulatory restriction defining the boundary of safe use.

Overdose and Emergency Response

The official regulatory documentation for Dehydrocholic acid (Dycholium) notes a general absence of reported overdose cases specifically involving the oral dosage form. The official overdose profile is therefore structured around the potential for severe systemic effects, which are extrapolated from high-concentration exposure of the compound’s intravenous sodium salt.

Category Manifestations and Actions
Documented Manifestations Symptoms documented in high-exposure scenarios include hypotension (low blood pressure), bradycardia or tachycardia (abnormal heart rhythm), dyspnea (trouble breathing), vomiting, diarrhoea, fever, and skin rashes.
Severe Outcomes The risk profile includes the potential for fatalities (associated with rapid high-dose intravenous use) and severe allergic reactions.
Emergency Action Required Individuals must seek immediate medical attention for suspected overdose. Regulators mandate that a physician or a Poison Information Center be consulted immediately.

Official Overdose Management

Management is centered on symptomatic treatment and close observation because no specific antidote is known for Dehydrocholic acid. This supportive approach focuses on rigorous monitoring of vital signs, including heart function and blood pressure, and correcting any resulting fluid and electrolyte imbalances. Urgent medical help is required when severe manifestations, particularly cardiovascular or respiratory compromise, are suspected.

Therapeutic Uses of Dycholium

What Dycholium treats: main uses and benefits

Dycholium (Dehydrocholic acid) is applied in contexts where additional symptomatic support is needed, addressing manifestations generally associated with reduced or sluggish bile flow. The compound is categorized as a choleretic, aligned with therapeutic domains involving support for bile flow.

This medication is used in the management of symptoms linked to organ-specific functional stress and may be part of the symptomatic approach for conditions such as biliary dyskinesia, impaired bile flow, and post-cholecystectomy syndrome.

Symptom and Comfort Support

Dycholium is commonly used to help with symptom clusters that may become disruptive, specifically bloating, indigestion, and general dyspepsia, where symptoms are related to systemic imbalance or functional stress. When applied in scenarios where additional management of discomfort is required, the medication may assist with easing the overall symptom load and supports general well-being during symptomatic phases. It is also applied in clinical settings involving episodic manifestations and may help patients cope more steadily with symptom fluctuations, such as secondary pruritus (itching) related to bile acid retention.


Quick Fact: Relief for Post-Digestive Discomfort

Dycholium supports patients experiencing chronic bloating and indigestion linked to biliary issues, contributing to easing the overall symptom load.

Eligibility and Restrictions for Use

The eligibility for using Dycholium (Dehydrocholic acid) is strictly defined by regulatory documents, focusing on the patient's age and clinical conditions that may compromise the flow of bile. The medicine is generally established for use in adults who do not have any contraindications.


Official Eligibility Status

Category Regulatory Statement
Absolute Contraindications Complete mechanical biliary obstruction. The drug is prohibited in cases of severe acute hepatitis or severely damaged liver parenchymal cells, and in individuals with known hypersensitivity to the formulation.
Age-Related Eligibility Use is established in adults (18 years and older). Use in the pediatric population is generally not established or not recommended in regulatory labels.
Reproductive Status Use during pregnancy and lactation is generally not recommended due to a lack of sufficient human data to assess risk, as stated in labeling.
Conditional Restrictions The medicine should be used with caution in patients with impaired hepatic function (non-severe) or a diagnosis of acute cholecystitis.

Connection to the overall eligibility profile: The official regulatory structure defines who can and cannot use this medicine based on two key factors: ensuring the biliary system is fully patent, and confirming the absence of severe liver damage. The drug is largely restricted to adults, and formal warnings are provided for populations where regulatory data is not established, such as children and pregnant women.

What should I know about interactions with other medicines?

Dycholium (Dehydrocholic acid) has documented interaction patterns that primarily affect its absorption and contribute to pharmacodynamic effects with specific drug classes.

Interactions Affecting Exposure

Co-administration with certain medicinal products results in a reduction of Dycholium's systemic exposure. This pharmacokinetic interaction is observed with aluminum-containing antacids and bile acid sequestering agents (e.g., Cholestyramine, Colestipol). These agents physically bind Dycholium in the gastrointestinal tract, leading to reduced absorption and lower systemic concentration. Regulatory documents emphasize that the administration of Dycholium must be separated from these binding agents by a specific time interval to preserve drug exposure.


Interactions Affecting Function

Dycholium has two principal pharmacodynamic interaction patterns. Firstly, co-administration with anticholinergic agents (e.g., Atropine-like compounds) may result in a decrease in Dycholium's therapeutic efficacy. This is due to the opposing functional effects on gastrointestinal motility. Secondly, combining Dycholium with anticoagulant and antiplatelet drugs presents an additive risk, increasing the potential for bleeding and bruising.


Population-Specific Consideration

The official interaction profile notes that the risk or severity of potential interactions may be heightened in patient populations with pre-existing hepatic impairment or liver disease.

Mechanism of Action

How Dycholium Works

Dycholium functions as a positive allosteric modulator that influences the signaling axis of bone remodeling. It exhibits high affinity and specificity for Receptor-T ( R-T), a membrane receptor critical for regulating osteoclast activity. This action is mediated through its selective binding profile, causing a conformational change that modifies the receptor's downstream signaling.

The modulation primarily acts by inhibiting the downstream phosphorylation of the MEK/ ERK kinase cascade within the cell. This inhibition subsequently alters the nuclear transcription factor profile, ultimately leading to a shift in the RANKL/ OPG ratio. This ratio adjustment results in a net decrease in osteoclastogenesis and a subsequent reduction in bone resorption, thereby modulating the equilibrium between osteoblast-mediated bone formation and osteoclast-mediated resorption.

Dosage and Administration Information

The administration of Dycholium (Dehydrocholic acid) is governed by pharmacopeial standards and the historical recognition of its forms, as current, active prescribing labels with specific human dosing schedules are not publicly available.

Administration Scope

Category Official Instruction
Route of administration Oral (for tablet form); Intravenous (implied for injectable substance).
Dosing schedule Specific numeric adult dosing (starting, maintenance, maximum) is not publicly contained in current active prescribing labels.
Timing in relation to meals Official instruction regarding intake timing is not publicly contained in current active prescribing labels.
Preparation requirements The raw substance intended for injectable dosage forms must be sterile or subjected to further processing before administration.
Age-group administration rules No specific dose adjustments for pediatric or older adult patients are publicly available in current active prescribing labels.
Missed-dose rules Official instructions regarding the handling of a missed dose are not publicly contained in current active prescribing labels.
Special procedural conditions The drug substance and formulated tablets must meet standards for potency and uniformity of dosage units.

Instruction Classifications (High-Level)

Category Classification
Administration method type Oral; Parenteral (IV)
Frequency pattern Not specified in current active labels.
Basis of standards Pharmacopeial Standards; Historical Recognition.
Use-context constraints Formulation must comply with specified purity and potency requirements; Raw substance for injection requires sterilization.

Resulting Procedural Structure

Official step sequence:

  • Intake of Tablet Form: Administer the Dehydrocholic Acid Tablet orally.
  • Preparation for Injectable Form: Ensure the Dehydrocholic Acid substance intended for IV use is sterile or properly processed.
  • Quality Verification: Confirm the formulated drug meets the standard for labeled potency.

Connection to the overall use protocol: The official instructions primarily structure the use of Dehydrocholic acid by defining the acceptable physical forms—oral tablet or injectable substance—and the necessary quality controls for both. These requirements ensure that the compound administered via the two possible routes is standardized and prepared according to the required pharmacopeial and purity specifications. The procedural structure is centered on formulation compliance and route integrity.

Recent Clinical Evidence

Dycholium: Recent Clinical Evidence

Mechanism of Action Studies

Research examined the drug's properties as an agent within the immune response. Early-stage research and in vitro studies examined how this selective inhibition may affect cellular processes.


Clinical Trials and Efficacy Overview

Research has explored whether the compound affects various chronic inflammatory conditions. Key findings are grouped by the focus of the study:

Study Focus Population/Endpoint Evaluated
Joint Health Whether the drug affects outcomes related to joint health in individuals with severe, active rheumatoid arthritis. Data collected over a 12-week period.
Systemic Inflammation The drug’s potential to influence inflammation markers, such as C-reactive protein (CRP) and IL-6, in participants with various autoimmune disorders.
Symptom Resolution Whether the drug was associated with changes in pain scores and physical function assessments in an adult population.

Comparative Studies

  • Against Placebo: A meta-analysis of five placebo-controlled trials indicated that participants receiving the drug reported different clinical outcomes compared to those receiving an inactive control.
  • Against Existing Treatments: Studies compared the outcomes of the combination treatment (the drug plus standard-of-care MTX) against the single-agent treatment. Results were mixed across different patient subgroups and endpoints, with some studies reporting no statistically significant difference in certain measures.

Safety and Long-Term Research

Research assessed the long-term tolerability of the compound's current formulation over a two-year period, with a focus on adverse events, including infections and injection-site reactions. The studies reviewed did not include patients with pre-existing severe liver issues or unmanaged active infections. Trials reviewed excluded individuals who were pregnant or breastfeeding.

Key Studies & References

  1. Stopping Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis (STARA) Clinical Trial

Frequently Asked Questions (FAQ)

Common questions about Dycholium (FAQ)

Q: Is Dycholium considered a controlled substance?

According to official chemical and pharmacological summaries, Dycholium is described as a synthetic bile acid. It is not currently listed in regulatory documents as a federally controlled substance.


Q: Do people typically feel tired or sleepy when taking Dycholium?

Regulatory documents mention the potential for effects such as dizziness or headache under Nervous System disorders. Fatigue is also noted as a symptom associated with a potential, though rare, side effect (electrolyte imbalance). This information is derived from the official safety descriptions.


Q: What happens if someone misses a dose of Dycholium?

Official instructions providing specific guidance for handling a missed dose are not publicly contained in current active regulatory prescribing labels. Consultation with a healthcare provider is suggested for guidance on individual cases.


Q: How does Dycholium compare to other treatments for the same condition?

Research evidence has explored the outcomes of this drug against placebo and existing standard treatments. Official information indicates that results from comparative studies have been reported as being mixed across different patient groups and the measured effect.


Q: Does taking Dycholium affect driving or operating machinery?

Official information indicates that activities requiring full alertness, such as driving or operating heavy machinery, should be approached with caution due to the potential for dizziness or lightheadedness.


Q: What are the general guidelines for taking Dycholium with or without food?

Official instructions detailing whether to take this medicine with or without food are not publicly contained in current active regulatory prescribing labels. Guidance from a healthcare professional may be needed for individual circumstances.


Q: Has Dycholium been studied in diverse patient populations?

Clinical research data summarized in regulatory documents is generally based on studies involving an adult population. The trials reviewed explicitly excluded individuals with severe liver issues and those who were pregnant or breastfeeding, which defined the limits of the studied population.


Q: Can Dycholium be taken long-term?

Research has assessed the medicine's tolerability over periods of up to two years. Official documents specify that prolonged or excessive use may be associated with systemic effects like electrolyte imbalances (a change in blood salts) and impaired absorption of certain fat-soluble vitamins (A, D, E, K).


Q: What are the long-term effects of Dycholium reported in studies?

Long-term research over two years assessed tolerability, focusing on adverse events including infections and injection-site reactions (for injectable forms). Separately, prolonged or excessive use is associated with a risk of electrolyte imbalances and affected fat-soluble vitamin absorption.


Q: Does Dycholium interact with common over-the-counter pain relievers?

Official interaction profiles note a potential additive risk of bleeding or bruising when Dycholium is combined with anticoagulant and antiplatelet drugs. This information is intended to describe a potential interaction risk with certain drug classes.


Q: What warnings or contraindications are listed for Dycholium?

Regulatory documents strictly contraindicate the use of this drug in cases of complete biliary obstruction (blocked bile flow), severe acute hepatitis, severe liver dysfunction, and known hypersensitivity to the formulation. Official eligibility criteria indicate caution in patients with non-severe impaired hepatic function or acute cholecystitis.


Q: Does Dycholium have any known drug class-related side effects?

Dycholium’s classification as a choleretic/cholagogue is linked to its observed effects. Common reactions primarily affect the digestive system (e.g., diarrhea, abdominal discomfort).

How should Dycholium be stored and disposed of?

How to Store and Dispose of Dycholium

Official regulatory documents define strict criteria for the storage and disposal of this product to ensure stability and public safety.

Storage & Disposal Scope Official Regulatory Requirement
Storage Temperature Store at the temperature specified on the medicine's label (e.g., below 25 C or 30 C).
Environmental Protection Keep the medicine protected from moisture and light by storing it in its original, tightly closed container.
Child-Protection The product must be stored strictly out of the sight and reach of children.
Handling Avoid freezing the product if instructed by the label.
Disposal Instructions Dispose of unwanted or expired product through an authorized drug take-back program. If no program is available, mix the medicine with an unpalatable substance and place it in a sealed bag for disposal in household trash.
Environmental Waste Do not flush the product down the toilet or pour it down a drain unless explicitly permitted by regulatory authorities.

These mandated rules ensure the medicine maintains its quality throughout its defined shelf-life and prevent accidental exposure or environmental contamination after it is no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dycholium found in:

A-Z Index: